BASE: a sustainable path for the University of Milano-Bicocca

Autor: Messa Cristina, Magatti Giacomo, Rossetti Massimiliano, Colleoni Matteo, Labra Massimo, Camatini Marina

Publikováno v: E3S Web of Conferences, Vol 48, p 04005 (2018)

Since its foundation, in 1998, the University of Milano-Bicocca has been pursuing the objective to make its structures sustainable from an environmental, social and economic point of view. To this end, in 2015 the University of Milano-Bicocca created

Externí odkaz: https://doaj.org/article/e2f179cd273946fba0f90c10f2dbad91

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.

Autor: Geyer CE Jr; NRG Oncology/NSABP Foundation, Pittsburgh; Department of Medicine, UPMC Hillman Cancer Center, Pittsburgh., Garber JE; Dana-Farber Cancer Institute, Harvard Medical School, Boston., Gelber RD; Dana-Farber Cancer Institute, Harvard Medical School, Boston; Harvard T.H. Chan School of Public Health, Boston; Frontier Science Foundation, Boston., Yothers G; NRG Oncology/NSABP Foundation, Pittsburgh; Department of Biostatistics, University of Pittsburgh, Pittsburgh, USA., Taboada M; Oncology Biometrics Department, AstraZeneca, Macclesfield., Ross L; Department of Data Management, Frontier Science (Scotland), Kincraig, Scotland, UK., Rastogi P; NRG Oncology/NSABP Foundation, Pittsburgh; Department of Medicine, UPMC Hillman Cancer Center, Pittsburgh., Cui K; Department of Oncology R&D, AstraZeneca, Gaithersburg, USA., Arahmani A; Research Operations Department, Breast International Group, Brussels, Belgium., Aktan G; Global Oncology Clinical Development, Merck and Co. Inc., Rahway, USA., Armstrong AC; Department of Medical Oncology, The Christie Hospital NHS Foundation Trust Manchester, UK., Arnedos M; European Organisation for Research and Treatment (EORTC), Brussels, Belgium; The Department of Medical Oncology, Institut Bergonie, Bordeaux, France., Balmaña J; Medical Oncology Department, Vall d'Hebron Institute of Oncology and Vall d'Hebron University Hospital, Barcelona, Spain., Bergh J; Department of Oncology-Pathology, Swedish Breast Cancer Group, Karolinska Institute and Breast Cancer Center, Karolinska University Hospital and Karolinska Comprehensive Cancer Center, Stockholm, Sweden., Bliss J; Department of Clinical Trials and Statistics Unit (ICR-CTSU), The Institute of Cancer Research, London, UK., Delaloge S; Department of Cancer Medicine, Institute Gustave Roussy and Unicancer Breast Group, Paris, France., Domchek SM; Department of Medicine, Basser Center for BRCA at the Abramson Cancer Center, University of Pennsylvania, Philadelphia, USA., Eisen A; Odette Cancer Centre, Department of Medicine, University of Toronto, Toronto, Canada., Elsafy F; Oncology Biometrics Department, AstraZeneca, Macclesfield., Fein LE; Department of Clinical Research, Instituto de Oncologia De Rosario, Santa Fe, Argentina., Fielding A; Department of Oncology R&D, AstraZeneca, Gaithersburg, USA., Ford JM; Department of Medicine/Oncology, Stanford University School of Medicine, Stanford., Friedman S; Facing Our Risk of Cancer Empowered, Tampa, USA., Gelmon KA; Department of Medical Oncology, BC Cancer, Vancouver, Canada., Gianni L; Department of Oncology, International Breast Cancer Study Group, Bern, Switzerland; Department of Medical Oncology, Ospedale Infermi AUSL della Romagna, Rimini, Italy., Gnant M; Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria., Hollingsworth SJ; Department of Late Development Oncology, AstraZeneca, Cambridge, UK., Im SA; Department of Internal Medicine, Cancer Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea., Jager A; Department of Medical Oncology, Dutch Breast Cancer Research Group, Utrecht, the Netherlands., Jóhannsson ÓÞ; Department of Medical Oncology, Landspítali University Hospital of Iceland, Icelandic Breast Cancer Group, Reykjavik, Iceland., Lakhani SR; Department of Anatomical Pathology, The University of Queensland Centre for Clinical Research and Pathology Queensland, Brisbane, Australia., Janni W; Department for Obstetrics and Gynecology, Universitaetsklinikum, University of Ulm, Ulm, Germany., Linderholm B; Department of Oncology, Sahlgrenska University Hospital, Gothenburg; Department of Oncology, The Institute of Clinical Sciences, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden., Liu TW; Division of Cancer Research, National Health Research Institutes, Taiwan Cooperative Oncology Group, Taipei City, Taiwan., Loman N; Department of Hematology, Oncology, and Radiation Physics, Swedish Association of Breast Oncologists, Skåne University Hospital, Lund, Sweden., Korde L; Clinical Investigations Branch, Division of Cancer Treatment and Diagnosis, The National Cancer Institute, Rockville, USA., Loibl S; Medicine and Research, German Breast Group, Neu-Isenburg; Medicine and Research, The Center for Hematology and Oncology Bethanien and Goethe University, Frankfurt, Germany., Lucas PC; NRG Oncology/NSABP Foundation, Pittsburgh; Department of Pathology, UPMC Hillman Cancer Center, Pittsburgh, USA., Marmé F; Medical Faculty Mannheim, Heidelberg University, Mannheim Germany and the German Breast Group, Neu-Isenburg, Germany., Martinez de Dueñas E; Médica Consorcio Hospitalario Provincial de Castellón, Servicio de Oncología, Castellón, Spain., McConnell R; Department of Data Management, Frontier Science (Scotland), Kincraig, Scotland, UK., Phillips KA; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne; Breast Cancer Trials, Australia and New Zealand, Newcastle, Australia., Piccart M; Department of Scientific Direction, Institut Jules Bordet, l'Université Libre de Bruxelles, Brussels., Rossi G; Department of Research and Development, Breast International Group, Brussels, Belgium., Schmutzler R; The Center for Familial Breast and Ovarian Cancer and the Center for Integrated Oncology, Faculty of Medicine, University Hospital Cologne, Cologne, Germany., Senkus E; Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk, Poland., Shao Z; Fudan University Shanghai Cancer Center, Shanghai, China., Sharma P; Department of Internal Medicine, Division of Medical Oncology, University of Kansas Medical Center, Westwood, USA., Singer CF; Department of OB/GYN and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria., Španić T; Department of Patient Advocacy, Europa Donna-The European Breast Cancer Coalition, Milan, Italy; Europa Donna Slovenia, Ljubljana, Slovenia., Stickeler E; Department of Obstetrics and Gynecology, University Hospital Aachen, Aachen, Germany., Toi M; Department of Breast Surgery Kyoto University Hospital, Kyoto, Japan., Traina TA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA., Viale G; Department of Pathology, University of Milan, European Institute of Oncology IRCCS, Milan., Zoppoli G; Internal Medicine Oncology Unit, Gruppo Oncologico Italiano di Ricerca Clinica, Parma; Università degli Studi di Genova and IRCCS Ospedale Policlinico San Martino, Genoa, Italy., Park YH; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea., Yerushalmi R; Department of Oncology, Institute of Oncology, Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, Petach Tikva; Faculty of Medicine, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel., Yang H; Department of Breast Surgery, The Cancer Hospital of the University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou., Pang D; Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China., Jung KH; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea., Mailliez A; Department of Medical Oncology, Breast Cancer Unit, Oscar Lambret Center, Lillie, France., Fan Z; Department of Breast Surgery, First Hospital of Jilin University, Jilin, China., Tennevet I; Department of Medical Oncology, Centre Henri Becquerel, Rouen, France., Zhang J; Breast Cancer Center, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China., Nagy T; Chemotherapy Department B, Országos Onkológiai Intézet, National Institute of Oncology, Budapest, Hungary., Sonke GS; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Sun Q; Department of Breast Surgery, Peking Union Medical College Hospital, Peking, China., Parton M; Breast Unit, Royal Marsden Hospital, London, UK., Colleoni MA; Division of Medical Senology, European Institute of Oncology (IEO), IRCCS, Milan., Schmidt M; Department of Obstetrics and Gynecology, University Medical Center Mainz, Mainz, Germany., Brufsky AM; NRG Oncology/NSABP Foundation, Pittsburgh; Department of Medicine, UPMC Hillman Cancer Center, Pittsburgh., Razaq W; Department of Internal Medicine, Section of Hematology/Oncology, Oklahoma University Health, Oklahoma City, USA., Kaufman B; The Breast Oncology Institute, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel., Cameron D; Edinburgh Cancer Research Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh., Campbell C; Department of Statistics and Programming, Frontier Science (Scotland), Kincraig, Scotland., Tutt ANJ; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London; The Breast Cancer Now Unit, Guy's Hospital Cancer Centre, King's College London, London, UK. Electronic address: andrew.tutt@icr.ac.uk.

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2022 Dec; Vol. 33 (12), pp. 1250-1268. Date of Electronic Publication: 2022 Oct 10.

The added value of whole-body magnetic resonance imaging in the management of patients with advanced breast cancer.

Autor: Zugni F; Post-graduation school in Radiodiagnostics, University of Milan, Milan, Italy., Ruju F; Department of Radiological Science and Radiation Therapy, European Institute of Oncology (IEO), Milan, Italy., Pricolo P; Department of Radiological Science and Radiation Therapy, European Institute of Oncology (IEO), Milan, Italy., Alessi S; Department of Radiological Science and Radiation Therapy, European Institute of Oncology (IEO), Milan, Italy., Iorfida M; Division of Medical Senology, European Institute of Oncology (IEO), Milan, Italy., Colleoni MA; Division of Medical Senology, European Institute of Oncology (IEO), Milan, Italy., Bellomi M; Department of Radiological Science and Radiation Therapy, European Institute of Oncology (IEO), Milan, Italy.; Division of Medical Senology, European Institute of Oncology (IEO), Milan, Italy.; Department of Oncology, University of Milan, Milan, Italy., Petralia G; Department of Radiological Science and Radiation Therapy, European Institute of Oncology (IEO), Milan, Italy.; Division of Medical Senology, European Institute of Oncology (IEO), Milan, Italy.; Department of Oncology, University of Milan, Milan, Italy.

Publikováno v: PloS one [PLoS One] 2018 Oct 12; Vol. 13 (10), pp. e0205251. Date of Electronic Publication: 2018 Oct 12 (Print Publication: 2018).

Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer.

Autor: Magnani L; Department of Surgery and Cancer, Imperial College London, London, UK., Frige G; Department of Experimental Oncology, European Institute of Oncology Milan, Italy., Gadaleta RM; Department of Surgery and Cancer, Imperial College London, London, UK., Corleone G; Department of Surgery and Cancer, Imperial College London, London, UK., Fabris S; Hematology Unit, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, IT., Kempe MH; Swammerdam Institute for Life Sciences, University of Amsterdam., Verschure PJ; Swammerdam Institute for Life Sciences, University of Amsterdam., Barozzi I; Genomics Division, Lawrence Berkeley National Laboratory, 1 Cyclotron Road, Berkeley, CA, USA., Vircillo V; Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Arcavacata di Rende (CS), Italy., Hong SP; Department of Surgery and Cancer, Imperial College London, London, UK., Perone Y; Department of Surgery and Cancer, Imperial College London, London, UK., Saini M; Division of Stem Cells and Cancer, Deutsches Krebsforschungszentrum (DKFZ), and Institute for Stem Cell Technology and Experimental Medicine GmbH, Heidelberg, Germany., Trumpp A; Division of Stem Cells and Cancer, Deutsches Krebsforschungszentrum (DKFZ), and Institute for Stem Cell Technology and Experimental Medicine GmbH, Heidelberg, Germany., Viale G; Division of Pathology, European Institute of Oncology and University of Milan, School of Medicine, Milan, Italy., Neri A; Hematology Unit, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, IT.; Department of Oncology and Hemato-oncology, University of Milano, Milan, IT., Ali S; Department of Surgery and Cancer, Imperial College London, London, UK., Colleoni MA; Division of Medical Senology, European Institute of Oncology, IEO, Milan, Italy., Pruneri G; Division of Pathology, European Institute of Oncology and University of Milan, School of Medicine, Milan, Italy., Minucci S; Department of Experimental Oncology, European Institute of Oncology Milan, Italy.; Department of Biosciences, University of Milano, Milan, IT.

Publikováno v: Nature genetics [Nat Genet] 2017 Mar; Vol. 49 (3), pp. 444-450. Date of Electronic Publication: 2017 Jan 23.

Oncoplastic Breast-Conserving Surgery for Tumors Larger than 2 Centimeters: Is it Oncologically Safe? A Matched-Cohort Analysis.

Autor: De Lorenzi F; Department of Plastic and Reconstructive Surgery, European Institute of Oncology, Milan, Italy. francesca.delorenzi@ieo.it., Loschi P; Department of Plastic and Reconstructive Surgery, European Institute of Oncology, Milan, Italy., Bagnardi V; Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy.; Department of Statistics and Quantitative Methods, University of Milan-Bicocca, Milan, Italy., Rotmensz N; Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy., Hubner G; Department of Plastic and Reconstructive Surgery, European Institute of Oncology, Milan, Italy., Mazzarol G; Division of Pathology and Laboratory Medicine, European Institute of Oncology, Milan, Italy., Orecchia R; Division of Radiotherapy, European Institute of Oncology, Milan, Italy., Galimberti V; Department of Surgery, European Institute of Oncology, Milan, Italy., Veronesi P; Department of Surgery, European Institute of Oncology, Milan, Italy., Colleoni MA; Medical Senology, European Institute of Oncology, Milan, Italy., Toesca A; Department of Surgery, European Institute of Oncology, Milan, Italy., Peradze N; Department of Surgery, European Institute of Oncology, Milan, Italy., Mario R; Department of Plastic and Reconstructive Surgery, European Institute of Oncology, Milan, Italy.

Publikováno v: Annals of surgical oncology [Ann Surg Oncol] 2016 Jun; Vol. 23 (6), pp. 1852-9. Date of Electronic Publication: 2016 Feb 02.